Salta al contenuto principale
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
IT
FR
EN
PT
NL
NB
DE
IT
Home
Company Press Releases
Company press releases
Registrati
Filtri
Filtri
Aggiorna
Ripristina
Icon After
Data
Toggle Visibility
Tutti
Oggi
Questa settimana
Questo mese
Custom date range
From
To
Topic
Toggle Visibility
Acquisition or disposal of the issuer’s own shares
Additional regulated information required to be disclosed under the laws of a Member State
Adjustment of interest rate
Alliances and agreements
Annual financial and audit Reports
Change in Capital
Changes in the rights attaching to the classes of shares or securities
Commercial operations
Commercial results
Corporate life
Dividend
Ex Date
General meeting / Board Meeting
Half yearly financial reports and audit reports/limited reviews
Home Member State
Income
Inside information
Joint venture
Journal / appointments
Legal
Major shareholding notifications
Mandatory notification of trade primary insiders
Meetings / events
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Non-regulatory press releases
Other financial transaction
Other subject
Payments to governments
Polls / Surveys
Products and services
Prospectus / admission document
Rating
Sales
Share history
Share introduction and issues
Takeover bids
Total number of voting rights and capital
Trends / Analyses
Provider
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Displaying 251 - 282 of 282 results
Released
Company
Title
Industry
Topic
02 Aug 2021
17:45 CEST
NICOX
Number of voting rights as of July 31, 2021
20103015 Pharmaceuticals
Corporate life
02 Aug 2021
17:45 CEST
NICOX
Nombre total de droits de vote au 31 juillet 2021
20103015 Pharmaceuticals
Corporate life
16 Jul 2021
07:30 CEST
NICOX
Nicox Provides Second Quarter 2021 Business and Financial Highlights and Strategic Update
20103015 Pharmaceuticals
New
16 Jul 2021
07:30 CEST
NICOX
Nicox : Point d’activité et résumé financier du second trimestre 2021 – Point sur la stratégie de la Société
20103015 Pharmaceuticals
New
13 Jul 2021
07:30 CEST
NICOX
Nicox Appoints Robert N. Weinreb, M.D. and Sanjay G. Asrani, M.D. to its Glaucoma Clinical Advisory Board
20103015 Pharmaceuticals
Corporate life
13 Jul 2021
07:30 CEST
NICOX
Nicox : Nomination du Dr. Robert N. Weinreb et du Dr. Sanjay G. Asrani au Comité consultatif clinique sur le glaucome de la Société
20103015 Pharmaceuticals
Corporate life
06 Jul 2021
07:30 CEST
NICOX
Nicox : Bilan semestriel du contrat de liquidité avec Kepler Cheuvreux
20103015 Pharmaceuticals
New
06 Jul 2021
07:30 CEST
NICOX
Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
20103015 Pharmaceuticals
New
05 Jul 2021
07:30 CEST
NICOX
Nicox : Paiement d'étape anticipé de 2 millions de dollars d’Ocumension Therapeutics dans le cadre de l'accord sur ZERVIATE®
20103015 Pharmaceuticals
New
05 Jul 2021
07:30 CEST
NICOX
Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment under ZERVIATE® Agreement
20103015 Pharmaceuticals
New
02 Jul 2021
07:30 CEST
NICOX
Nicox : Dernière visite du dernier patient dans l’étude de phase 2b Mississippi sur le NCX 4251 dans la blépharite
20103015 Pharmaceuticals
New
02 Jul 2021
07:30 CEST
NICOX
Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial
20103015 Pharmaceuticals
New
01 Jul 2021
17:45 CEST
NICOX
Number of voting rights as of June 30, 2021
20103010 Biotechnology
Corporate life
01 Jul 2021
17:45 CEST
NICOX
Nombre de droits de vote au 30 juin 2021
20103010 Biotechnology
Corporate life
01 Jul 2021
07:30 CEST
NICOX
Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trial
20103010 Biotechnology
New
01 Jul 2021
07:30 CEST
NICOX
Nicox : Réduction significative de la pression intraoculaire avec le NCX 470 démontrée dans l’étude de phase 2 Dolomites dans le glaucome
20103010 Biotechnology
New
25 Jun 2021
07:30 CEST
NICOX
Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates
20103010 Biotechnology
New
25 Jun 2021
07:30 CEST
NICOX
Nicox : Approbation de VYZULTA® (solution ophtalmique de latanoprostène bunod), 0,024% dans les Emirats arabes unis par son partenaire Bausch + Lomb
20103010 Biotechnology
New
23 Jun 2021
17:45 CEST
NICOX
Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the World Glaucoma E-Congress 2021
20103010 Biotechnology
-
23 Jun 2021
17:45 CEST
NICOX
Nicox : Présentation au World Glaucoma E-Congress 2021 des résultats de l’étude de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome
20103010 Biotechnology
-
01 Jun 2021
17:45 CEST
NICOX
Number of voting rights as of May 31, 2021
20103010 Biotechnology
Corporate life
01 Jun 2021
17:45 CEST
NICOX
Nombre de droits de vote au 31 mai 2021
20103010 Biotechnology
Corporate life
01 Jun 2021
07:30 CEST
NICOX
Nicox : Achèvement du recrutement pré-défini des patients dans l’étude de phase 2b Mississippi pour le NCX 4251 dans la blépharite
20103010 Biotechnology
New
01 Jun 2021
07:30 CEST
NICOX
Nicox’s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trial
20103010 Biotechnology
New
05 May 2021
07:30 CEST
NICOX
Nicox : Partenariat avec Laboratorios Grin pour ZERVIATE au Mexique
20103010 Biotechnology
New
05 May 2021
07:30 CEST
NICOX
Nicox partners with Laboratorios Grin to bring ZERVIATE to Mexico
20103010 Biotechnology
New
04 May 2021
07:30 CEST
NICOX
Nicox : Lancement de VYZULTA® (solution ophtalmique de latanoprostène bunod), 0,024% à Taiwan par son partenaire Bausch + Lomb - Approbation de VYZULTA® au Qatar
20103010 Biotechnology
New
04 May 2021
07:30 CEST
NICOX
Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan and Receives Approval in Qatar
20103010 Biotechnology
New
03 May 2021
17:45 CEST
NICOX
Number of voting rights as of April 30, 2021
20103010 Biotechnology
Corporate life
03 May 2021
17:45 CEST
NICOX
Nombre total de droits de vote au 30 avril 2021
20103010 Biotechnology
Corporate life
30 Apr 2021
07:30 CEST
NICOX
Nicox Updates on Fera Pharmaceuticals’ Continuing Evaluation of Naproxcinod
20103010 Biotechnology
New
30 Apr 2021
07:30 CEST
NICOX
Nicox : Point sur les travaux de Fera Pharmaceuticals sur le naproxcinod
20103010 Biotechnology
New
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Paginazione
«
« First
‹
‹‹
4
5
6
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
your account
section or
create an account
.
Home
Mercati
Amsterdam
Cash Products
Stocks
AEX index Stocks
AEX ESG Stocks
Indices
Funds
Bonds
ETFs
Structured products
Derivative products
Index options
Index futures
Stock options
Dividend derivatives
Stock futures
Quote Vendor Codes
Company regulated news
Latest
Archive
Brussels
Cash products
Stocks
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indices
Bonds
ETFs
Structured Products
Derivative products
Index futures
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisbon
Cash Products
Stocks
Euronext regulated
Euronext Access
PSI Stocks
Indices
Bonds
Derivative products
Index futures
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Milan
Cash Products
Azioni
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Azioni
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Fondi
Derivative products
Tutti
Futures su indici
Opzioni su indici
Opzioni su azioni
Futures su azioni
Dividend futures
Quote Vendor Codes
IPOs
Oslo
Cash Products
Stocks
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX stocks
OBX ESG Stocks
OSEBX stocks
OSEFX Stocks
Seafood Stocks
Shipping Stocks
Equity indices
Bonds
Oslo Børs
Nordic Alternative Bond Market
Bond indices
ETFs
Funds
Derivatives
Derivative products
Quote Vendor Codes
Company regulated news
Latest
Archive
Financial calendars
Primary insiders
Paris
Cash Products
Stocks
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indices
Bonds
ETFs
Structured products
Derivative products
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Azioni
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Company regulated news
Latest
Archive
IPOs
All IPOs
Listing sponsors
Euronext Tech Leaders
Family business
Indices
Directory
ESG indices
Indices documents
Indices news
Index consultations
Contact Euronext indices
ETFs
Directory
ESG ETFs
Funds
Directory
ESG Funds
Oslo Mutual Funds
Fixed Income
ESG Bonds
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Structured Products
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Equity Derivatives
Index Futures
Index Options
Stock Options
Stock Futures
Dividend Derivatives
ETF Options
Contracts specifications
Tick Sizes
Wholesale Trading
Quote vendor codes
Commodities
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Trading calendars
Delivery
Wholesale Trading
Commitments of Traders (CoT) report
Contracts specifications
Quote vendor codes
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Resources
Statistics & reports
Quality of execution
Trading hours & Holidays
Contract specifications
Quote vendor codes
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Market events
Suspended instruments
Stressed Market Conditions
Breach of Double Cap limits
Exceptional Market Conditions
Miscellaneous short messages
Market status
Members list
Issuers compliance
Where to find